Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
| Country | Cayman Islands |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 99 |
| CEO | Rick E. Winningham M.B.A. |
Contact Details
Address: Ugland House, South Church Street George Town, Grand Cayman, E9 KY1-1104 Cayman Islands | |
| Phone | 650-808-6000 |
| Website | theravance.com |
Stock Details
| Ticker Symbol | TBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583107 |
| CUSIP Number | G8807B106 |
| ISIN Number | KYG8807B1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rick E. Winningham M.B.A. | Chairman and Chief Executive Officer |
| Aziz Sawaf C.F.A. | Senior Vice President and Chief Financial Officer |
| Stuart Knight | Vice President of IT&I and Chief Information Officer |
| Gail B. Cohen | Vice President of Corporate Communications and Investor Relations |
| Brett A. Grimaud Esq. | Senior Vice President, General Counsel and Secretary |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial and Medical Affairs |
| Stacy L. Pryce | Senior Vice President and Chief Strategy Officer |
| Dr. Aine Miller Ph.D. | SVice President of Dev., VP of Regu., Quality, Clinical Safety and Pharmacovigilance and Head of Ireland Office |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 3, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 1, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 16, 2024 | 8-K | Current Report |